Galapagos (GLPG) Receives a Buy from Nomura


In a report released today, Christopher Marai from Nomura maintained a Buy rating on Galapagos (GLPG), with a price target of $290.00. The company’s shares closed last Thursday at $203.08.

According to TipRanks.com, Marai is a 4-star analyst with an average return of 3.3% and a 50.6% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Deciphera Pharmaceuticals, and Alexion Pharmaceuticals.

Galapagos has an analyst consensus of Moderate Buy, with a price target consensus of $229.97, representing an 11.3% upside. In a report issued on May 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $302.00 price target.

See today’s analyst top recommended stocks >>

Based on Galapagos’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $98.17 million and GAAP net loss of $50.6 million. In comparison, last year the company earned revenue of $33.05 million and had a GAAP net loss of $48.66 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Read More on GLPG:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts